The UK took a step closer to becoming a European hub for medical cannabis today after London-based Celadon Pharmaceuticals became the first British company to clear a regulatory hurdle to begin manufacturing the substance.
Celadon Pharmaceuticals was granted a Good Manufacturing Practice or GMP registration by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to produce medical cannabis that’s high in Tetrahydrocannabinol, the element of the plant that contains psychoactive properties used to treat chronic pain and neurological disorders.
